---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-072950"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2023-06-20T23:59:59+00:00"
generated_at: "2026-06-13T20:37:15.538257+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# BrainStorm appoints Nir Naor as Board member and Audit Committee chair; Taub resigns

## Summary
- Malcolm Taub resigned from Board effective June 15, 2023; decision not due to any disagreement with the Company.
- Nir Naor elected to Board effective June 20, 2023, as new independent director, Audit Committee chair, and GNC Committee member.
- Naor receives initial grant of 11,999 restricted shares plus annual stock option or restricted stock awards, vesting monthly over 12 months.
- Naor has over 20 years of finance and biotech experience, including CFO of Arbor Pharmaceuticals and senior roles at UCB and AstraZeneca.

## SEC filing metadata
- accession: 0001104659-23-072950
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2023-06-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465923072950/0001104659-23-072950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465923072950/tm2319248d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-072950
- JSON: https://secwatch.observer/filing/0001104659-23-072950.json
- Plain text: https://secwatch.observer/filing/0001104659-23-072950.txt

## Key facts
- Executive change
  Nir Naor was elected as Director, Chair of Audit Committee at BRAINSTORM CELL THERAPEUTICS INC..
  - Action: elected
  - Role: Director, Chair of Audit Committee
  source text: On June 19, 2023, the Board elected Nir Naor to serve as a member of the Board, effective June 20, 2023, filling the vacancy created by Mr. Taub’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465923072950/0001104659-23-072950-index.htm
- Executive change
  Malcolm Taub resigned as Director at BRAINSTORM CELL THERAPEUTICS INC..
  - Action: resigned
  - Role: Director
  source text: On June 15, 2023, Malcolm Taub notified the Board of Directors (the “Board”) of Brainstorm Cell Therapeutics Inc. (the “Company”) of his decision to resign from the Company’s Board, and all committees thereof, effective as of the close of business on June 15, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465923072950/0001104659-23-072950-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.